The hematologic oncologist from Memorial Sloan Kettering Cancer Center discussed factors to consider in selecting CAR T-cell therapies.
This content originally appeared on our sister site, OncLive.
OncLive spoke with Jae Park, MD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, about factors to consider when selecting among the available CAR T-cell therapies for the treatment of patients with mantle cell lymphoma.
Differences in these agents can be observed with respect to their individual safety profiles, according to Park. For example, lisocabtagene maraleucel (liso-cel; Breyanzi) is associated with fewer reports of cytokine release syndrome (CRS) and neurotoxicity; however, it is still important to review the manufacturing details, as this agent has now been commercialized, Park explains. Additionally, although axicabtagene ciloleucel (axi-cel; Yescarta) has a faster turnaround time with regard to manufacturing, resulting in more rapid availability, higher rates of CRS and neurotoxicity have also been reported with the product, Park notes.
The key factors to consider when making treatment decisions often include turnaround time, manufacturing success, and reliability of delivery, as well as the frequency and intensity of the monitoring required for patients, Park explains. Despite the complicated decision-making process, having a range of options available for patients is beneficial, Park concludes.